IHS Says Next Healthcare Treatment Wave Breakthroughs Coincide With Cost Restraint In Western Europe
IHS Inc. (NYSE: IHS) said that an immense wave of progress for patients is posing increasingly challenging questions for policymakers, payers and healthcare stakeholders in Western Europe. The research firm prepared a Life Sciences report, titled, ‘Comparative Healthcare Financing Trends In Europe: A Retrospective and Forward-Looking View.'
According to IHS report, it analyzed the financing trends between the two periods, i.e. 2010 – 2014 and 2015 – 2020 involving countries like France, German, Poland, the Netherlands, the United Kingdom and Spain. It found that the diverse healthcare systems set, political situations, and economic conditions allowed them to model pricing structures through different systems.
The research firm's senior consultant, Cameron Lockwood, said, "One of our key findings is that the next wave of treatment breakthroughs coincides with a period when cost containment is firmly on the healthcare system agenda. A wealth of new treatments and innovations, specifically in the cancer field, will reach the market at a time when many countries are on cost-saving drives."
IHS said emerging new treatments, as well as continued economic recovery would contribute to an uptick in public reimbursement spending on pharmaceuticals. The research organization said that in some countries, this spending is predicted to be less as a share of overall public health expenditure compared to 2014, raising question marks over the ability to finance innovations in therapy.
Also, between 2015 and 2020, growth in public healthcare expenditure would eitherlikely to remain negative or subdued.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.